Science journalism by Leonid Schneider, on research integrity and academic publishing in life sciences and biomedicine
As a young Wunderkind, Josef Penninger discovered the ACE2 receptor. Now he invented the cure for the coronavirus which will work in his hands where Big Pharma failed. He was never found guilty of research misconduct and never retracted a paper. Dr Penninger is a Genius making a COVID-19 vaccine.
A former Harvard postdoc from the lab of George Q Daley tells his story.
Israeli scientists discovered a cure for coronavirus! Their proprietary PLX cells from placenta deliver 100% survival rate both against COVID-19 and a nuclear holocaust. The stocks soar.
In this 3rd instalment of her Celixir investigation, Patricia Murray learns whose side the British authority MHRA is on. Not the patients’, and certainly not on the side of facts.
Smut Clyde studies two Chinese research groups to understand how TCM can be used to create modern Photoshop art.
Catherine Verfaillie is a zombie scientist: her past stem cell research long discredited, but she still is an influential and very well funded star of Belgian science. Now Elisabeth Bik had a fresh new look at Verfaillie’s papers
Liverpool professor Patricia Murray continues investigating shady dealings of the regmed company Celixir, owned by struck-off dentist Ajan Reginald and Nobelist Sir Martin Evans
Patricia Murray uncovers the business secrets of the Nobelist Martin Evans and his partner Ajan Reginald. It seems the magic iMP cells used to treat patients in Greece were drawn from the blood of patients in Swansea, for the purpose of a secret PhD thesis. There is no serious science behind it, only serious investor money and a fraudulent patent.
Dentistry professors at UCLA published manipulated data in top-level journals. When a colleague reported them, the university retaliated against the whistleblower.
Sir Martin Evans, winner of Nobel prize 2007, founded in 2009 the stem cell start-up Celixir, together with a struck-off dentist Ajan Reginald. With the help of the British heart surgeon Stephen Westaby, they ran a very profitable clinical trial in Greece, which now moved into UK.
